Cargando…

Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model

BACKGROUND: Thiazolidinediones exert anti-inflammatory and anti-oxidative roles and attenuate atherosclerosis by mechanisms partially independent of their metabolizing actions. High doses of angiotensin type 1 receptor (AT(1)R) blocker losartan (LST) seem to promote fat cell formation by preserving...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hernandez-Trujillo, Y, Rodriguez-Esparragon, F, Macias-Reyes, A, Caballero-Hidalgo, A, Rodriguez-Perez, Jose C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266907/ https://www.ncbi.nlm.nih.gov/pubmed/18302760 http://dx.doi.org/10.1186/1475-2840-7-3

Ejemplares similares

Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro
por: Ren, Liqun, et al.
Publicado: (2011)

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
por: Vitale, Cristiana, et al.
Publicado: (2005)

Effects of Losartan on expression of connexins at the early stage of atherosclerosis in rabbits
por: Ruan, Li-ming, et al.
Publicado: (2010)

Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
por: Atamer, Y., et al.
Publicado: (2013)

CD36, a scavenger receptor implicated in atherosclerosis
por: Park, Young Mi
Publicado: (2014)

Losartan Interactions with 2-Hydroxypropyl-β-CD
por: Palli, Vasiliki, et al.
Publicado: (2022)

Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats
por: Lu, Xiao, et al.
Publicado: (2010)

Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
por: Lee, Bok-Soo, et al.
Publicado: (2012)

In vivo effects of rosiglitazone in a human neuroblastoma xenograft
por: Cellai, I, et al.
Publicado: (2010)

Role of the Scavenger Receptor CD36 in Accelerated Diabetic Atherosclerosis
por: Navas-Madroñal, Miquel, et al.
Publicado: (2020)

Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury: A Randomized Clinical Trial
por: Puskarich, Michael A., et al.
Publicado: (2022)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits
por: LI, CHEN, et al.
Publicado: (2015)

Associations between CD36 gene polymorphisms and susceptibility to coronary artery heart disease
por: Zhang, Y., et al.
Publicado: (2014)

Endothelial Cell CD36 Reduces Atherosclerosis and Controls Systemic Metabolism
por: Rekhi, Umar R., et al.
Publicado: (2021)

Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis
por: Seijkens, Tom T.P., et al.
Publicado: (2018)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
por: Leonard, Charles E., et al.
Publicado: (2020)

Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
por: Varghese, Anitha, et al.
Publicado: (2009)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

CD36 overexpression: a possible etiopathogenic mechanism of atherosclerosis in patients with prediabetes and diabetes
por: Lopez-Carmona, M. D., et al.
Publicado: (2017)

Losartan inhibits hyposmotic-induced increase of I(Ks) current and shortening of action potential duration in guinea pig atrial myocytes
por: Gao, Jie, et al.
Publicado: (2020)

Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: In vivo and ex vivo studies
por: Couto, Janaína A, et al.
Publicado: (2010)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1α-LIPIN 1 pathway and increasing CD36 through Nrf2
por: Barroso, Emma, et al.
Publicado: (2020)

Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats
por: Failli, Paola, et al.
Publicado: (2009)

CD36 Inhibitors Reduce Postprandial Hypertriglyceridemia and Protect against Diabetic Dyslipidemia and Atherosclerosis
por: Geloen, Alain, et al.
Publicado: (2012)

Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation
por: Hsu, Yaw-Wen, et al.
Publicado: (2021)

Losartan-induced Pancreatitis
por: Anwar, Shamsuddin M, et al.
Publicado: (2019)

Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study
por: Ma, Weina, et al.
Publicado: (2019)

Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6
por: JI, FAHE, et al.
Publicado: (2014)

Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)
por: García-García, Héctor M., et al.
Publicado: (2011)

Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study
por: Heier, Martin, et al.
Publicado: (2015)

Regional Variation in Genetic Control of Atherosclerosis in Hyperlipidemic Mice
por: Jones, Michael B., et al.
Publicado: (2020)

Role of CD36 in cancer progression, stemness, and targeting
por: Guerrero-Rodríguez, Sandra L., et al.
Publicado: (2022)

Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up
por: Novo, Salvatore, et al.
Publicado: (2013)

Is the combination of enalapril and losartan irrational?
por: Parmar, D.M., et al.
Publicado: (2008)

Lack of association between mutation in IL36RN and palmoplantar pustular psoriasis in Chinese patients()()
por: Xiaoling, Yu, et al.
Publicado: (2019)

Comparison of the GPVI inhibitors losartan and honokiol
por: Onselaer, Marie-Blanche, et al.
Publicado: (2019)

Rosiglitazone ameliorates acute hepatic injury via activating the Nrf2 signaling pathway and inhibiting activation of the NLRP3 inflammasome
por: Ma, Ling, et al.
Publicado: (2022)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2gms423jffjgb6s100jrsnefdf